Floating Button
Home Capital Tong's Portfolio

Vaccine and 'work' hesitancies are the next challenge

Asia Analytica
Asia Analytica • 15 min read
Vaccine and 'work' hesitancies are the next challenge
Positively, data shows that current approved vaccines remain highly effective against variant infections.
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Risks for stocks are elevated. Few would debate this. Valuations for Standard & Poor’s 500 stocks — according to data service provider FactSet, currently at 21.4 times forward earning — are higher than both the five- and 10-year averages of 18.1 and 16.2 times respectively.

Yet, US stocks have been inching inexorably higher this year — even though there is intermittent profit-taking — and leading global markets broadly higher. Case in point: The market saw another sharp selloff last Monday but recouped lost ground in the following days. All three major bellwether indices — the Dow Jones Industrial Average, S&P 500 index and Nasdaq Composite — remain not too far from all-time record-high levels.

A main reason behind last week’s volatility is fears that the Delta variant, which is driving a renewed surge in Covid-19 cases, will derail, or at least delay, the global economic recovery. Indeed, we are seeing the re-imposition of more stringent restrictions in parts of the world, particularly where the percentage of population vaccinated remains low.

×
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2026 The Edge Publishing Pte Ltd. All rights reserved.